Halozyme Therapeutics share price today
(NASDAQ: HALO)

Name: Halozyme Therapeutics Share Price Today (NASDAQ: HALO) - Halozyme Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Halozyme Therapeutics share price is $55.63 & ₹4,811.44 as on 24 Jan 2025, 2.30 'hrs' IST

$55.63

▲

0.35

(0.63%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Halozyme Therapeutics share price in Dollar and Rupees. Guide to invest in Halozyme Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Halozyme Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Halozyme Therapeutics share price movements

Today's Low: $54.96
Today's High: $55.86
$55.63
1.2%
Downside
Day's Volatility :1.6%
Upside
0.4%
52 Weeks Low: $33.15
52 Weeks High: $65.53
$55.63
40.41%
Downside
52 Weeks Volatility :49.41%
Upside
15.11%

Halozyme Therapeutics Returns

Period	Halozyme Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	12.24%	-5.5%	0.0%
6 Months	-1.69%	-4.3%	0.0%
1 Year	60.19%	1.6%	0.0%
3 Years	64.87%	9.8%	-11.0%

Halozyme Therapeutics Key Statistics

in dollars & INR

Previous Close	$55.28
Open	$55.22
Today's High	$55.855
Today's Low	$54.96
Market Capitalization	$7.1B
Today's Volume	$1.1M
52 Week High	$65.5327
52 Week Low	$33.15
Revenue TTM	$947.4M
EBITDA	$553.0M
Earnings Per Share (EPS)	$3.02
PE Ratio	18.52
Profit Margin	41.43%
Quarterly Earnings Growth YOY	0.72%
Return On Equity TTM	111.83%

How to invest in Halozyme Therapeutics Stock (HALO) from India?

It is very easy for Indian residents to invest directly in Halozyme Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Halozyme Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Halozyme Therapeutics or HALO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Halozyme Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Halozyme Therapeutics shares which would translate to 0.016 fractional shares of Halozyme Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Halozyme Therapeutics, in just a few clicks!

Returns in Halozyme Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Halozyme Therapeutics investment value today

Current value as on today

₹1,65,254

Returns

₹65,254

(+65.25%)

Returns from Halozyme Therapeutics Stock

₹61,200 (+61.2%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Halozyme Therapeutics

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Halozyme Therapeutics on INDmoney from India has grown in the last 30 days as on Jan 24, 2025. 0% more investors are searching Halozyme Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Halozyme Therapeutics

BlackRock Inc
13.70%
Vanguard Group Inc
10.14%
State Street Corp
5.21%
Snyder Capital Management LP
3.19%
AllianceBernstein L.P.
2.68%
Artisan Partners Limited Partnership
2.46%

Analyst Recommendation on Halozyme Therapeutics

Buy

82%Buy

17%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Halozyme Therapeutics(by analysts ranked 0 to 5 stars)

Based on 17 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Halozyme Therapeutics

What analysts predicted

Upside of 16.39%

Target:

$64.75

Current:

$55.63

Insights on Halozyme Therapeutics

Price Movement
In the last 1 month, HALO stock has moved up by 17.2%
Increasing Revenue
Revenue is up for the last 3 quarters, 195.87M → 290.08M (in $), with an average increase of 17.8% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, 76.82M → 137.01M (in $), with an average increase of 24.8% per quarter
HALO vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 95.4% return, outperforming this stock by 32.3%

Halozyme Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$151.9M	↓ 52.04%
Net Income	$-80.3M	↓ 227.57%
Net Profit Margin	-52.9%	↓ 72.79%

	FY19	Y/Y Change
Revenue	$196.0M	↑ 29.06%
Net Income	$-72.2M	↓ 10.07%
Net Profit Margin	-36.86%	↑ 16.04%

	FY20	Y/Y Change
Revenue	$267.6M	↑ 36.53%
Net Income	$129.1M	↓ 278.69%
Net Profit Margin	48.24%	↑ 85.1%

	FY21	Y/Y Change
Revenue	$443.3M	↑ 65.67%
Net Income	$402.7M	↑ 211.97%
Net Profit Margin	90.84%	↑ 42.6%

	FY22	Y/Y Change
Revenue	$660.1M	↑ 48.91%
Net Income	$202.1M	↓ 49.81%
Net Profit Margin	30.62%	↓ 60.22%

	FY23	Y/Y Change
Revenue	$829.3M	↑ 25.62%
Net Income	$281.6M	↑ 39.31%
Net Profit Margin	33.96%	↑ 3.34%

	Q2 FY23	Q/Q Change
Revenue	$221.0M	↑ 36.32%
Net Income	$74.8M	↑ 88.7%
Net Profit Margin	33.82%	↑ 9.39%

	Q3 FY23	Q/Q Change
Revenue	$216.0M	↓ 2.26%
Net Income	$81.8M	↑ 9.48%
Net Profit Margin	37.88%	↑ 4.06%

	Q4 FY23	Q/Q Change
Revenue	$230.0M	↑ 6.48%
Net Income	$85.4M	↑ 4.34%
Net Profit Margin	37.12%	↓ 0.76%

	Q1 FY24	Q/Q Change
Revenue	$195.9M	↓ 14.85%
Net Income	$76.8M	↓ 10.03%
Net Profit Margin	39.22%	↑ 2.1%

	Q2 FY24	Q/Q Change
Revenue	$231.4M	↑ 18.11%
Net Income	$93.2M	↑ 21.38%
Net Profit Margin	40.3%	↑ 1.08%

	Q3 FY24	Q/Q Change
Revenue	$290.1M	↑ 25.39%
Net Income	$137.0M	↑ 46.94%
Net Profit Margin	47.23%	↑ 6.93%

	FY18	Y/Y Change
Profit	$141.7M	↓ 50.35%

	FY19	Y/Y Change
Profit	$150.4M	↑ 6.15%

	FY20	Y/Y Change
Profit	$224.2M	↑ 49.04%

	FY21	Y/Y Change
Profit	$361.9M	↑ 61.4%

	FY22	Y/Y Change
Profit	$520.8M	↑ 43.91%

	FY23	Y/Y Change
Profit	$636.9M	↑ 22.29%

	Q2 FY23	Q/Q Change
Profit	$171.0M	↑ 34.65%

	Q3 FY23	Q/Q Change
Profit	$161.2M	↓ 5.71%

	Q4 FY23	Q/Q Change
Profit	$177.7M	↑ 10.25%

	Q1 FY24	Q/Q Change
Profit	$149.8M	↓ 15.73%

	Q2 FY24	Q/Q Change
Profit	$174.0M	↑ 16.15%

	Q3 FY24	Q/Q Change
Profit	$240.7M	↑ 38.32%

	FY18	Y/Y Change
Operating Cash Flow	$-49.5M	↓ 136.93%
Investing Cash Flow	$2.5M	↓ 101.52%
Financing Cash Flow	$-63.8M	↓ 148.46%

	FY19	Y/Y Change
Operating Cash Flow	$-85.4M	↑ 72.57%
Investing Cash Flow	$-5.5M	↓ 322.58%
Financing Cash Flow	$153.2M	↓ 340.16%

	FY20	Y/Y Change
Operating Cash Flow	$55.5M	↓ 164.92%
Investing Cash Flow	$78.4M	↓ 1512.04%
Financing Cash Flow	$-106.3M	↓ 169.37%

	FY21	Y/Y Change
Operating Cash Flow	$299.4M	↑ 439.98%
Investing Cash Flow	$-406.3M	↓ 618.53%
Financing Cash Flow	$77.9M	↓ 173.26%

	FY22	Y/Y Change
Operating Cash Flow	$240.1M	↓ 19.81%
Investing Cash Flow	$-487.0M	↑ 19.87%
Financing Cash Flow	$362.4M	↑ 365.38%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$66.8M	↓ 23.14%
Investing Cash Flow	$55.0M	↓ 191.41%
Financing Cash Flow	$2.4M	↓ 101.49%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$132.4M	↑ 98.1%
Investing Cash Flow	$-83.5M	↓ 251.74%
Financing Cash Flow	$4.1M	↑ 67.66%

Halozyme Therapeutics Technicals Summary

Sell

Neutral

Buy

Halozyme Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Halozyme Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Halozyme Therapeutics, Inc.	15.09%	-1.69%	60.19%	64.87%	188.37%
Biontech Se	0.91%	34.01%	18.85%	-26.4%	246.9%
Regeneron Pharmaceuticals, Inc.	-4.82%	-36.95%	-28.33%	12.74%	100.35%
Vertex Pharmaceuticals Incorporated	4.86%	-13.58%	-0.46%	88.45%	88.24%
Alnylam Pharmaceuticals, Inc.	9.57%	13.5%	44.91%	103.56%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Halozyme Therapeutics, Inc.	18.52	18.52	-2.5	4.13	1.12	0.15	NA	3.56
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Halozyme Therapeutics, Inc.	Buy	$7.1B	188.37%	18.52	41.43%
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Organization	Halozyme Therapeutics
Employees	373
CEO	Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Industry	Health Technology

Management People of Halozyme Therapeutics

Name	Title
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.	President, CEO & Director
Dr. Michael J. LaBarre Ph.D.	Senior VP & CTO
Mr. Mark Snyder Esq.	Senior VP & Chief Legal Officer
Ms. Cortney Caudill M.B.A.	Chief Operations Officer
Ms. Tram Bui	Head of Investor Relations & Corporate Communications
Ms. Amy Marinne Fox	Chief Human Resources Officer
Mr. Gary Grote	Chief Commercial Officer
Dr. Christopher Wahl M.B.A., M.D.	Chief Business Officer
Dr. Charles P. Theuer M.D., Ph.D.	Chief Medical Officer

Important FAQs about investing in Halozyme Therapeutics (HALO) from India :

What is Halozyme Therapeutics share price today?

Halozyme Therapeutics share price today stands at $55.63, Open: $55.22 ; Previous Close: $55.28 ; High: $55.86 ; Low: $54.96 ; 52 Week High: $65.53 ; 52 Week Low: $33.15. The stock opens at $55.22, after a previous close of $55.28. The stock reached a daily high of $55.86 and a low of $54.96, with a 52-week high of $65.53 and a 52-week low of $33.15.

Can Indians buy Halozyme Therapeutics shares?

Yes, Indians can invest in the Halozyme Therapeutics (HALO) from India.

With INDmoney, you can buy Halozyme Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Halozyme Therapeutics at zero transaction cost.

How can I buy Halozyme Therapeutics shares from India?

It is very easy to buy Halozyme Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Halozyme Therapeutics be purchased?

Yes, you can buy fractional shares of Halozyme Therapeutics with INDmoney app.

What are the documents required to start investing in Halozyme Therapeutics stocks?

To start investing in Halozyme Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.